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Background: A postpartum hemorrhage prevention program to increase uterotonic coverage for home and facility
births was introduced in two districts of Liberia. Advance distribution of misoprostol was offered during antenatal
care (ANC) and home visits. Feasibility, acceptability, effectiveness of distribution mechanisms and uterotonic
coverage were evaluated.
Methods: Eight facilities were strengthened to provide PPH prevention with oxytocin, PPH management and
advance distribution of misoprostol during ANC. Trained traditional midwives (TTMs) as volunteer community
health workers (CHWs) provided education to pregnant women, and district reproductive health supervisors
(DRHSs) distributed misoprostol during home visits. Data were collected through facility and DRHS registers.
Postpartum interviews were conducted with a sample of 550 women who received advance distribution of
misoprostol on place of delivery, knowledge, misoprostol use, and satisfaction.
Results: There were 1826 estimated deliveries during the seven-month implementation period. A total of 980
women (53.7%) were enrolled and provided misoprostol, primarily through ANC (78.2%). Uterotonic coverage rate
of all deliveries was 53.5%, based on 97.7% oxytocin use at recorded facility vaginal births and 24.9% misoprostol
use at home births. Among 550 women interviewed postpartum, 87.7% of those who received misoprostol and
had a home birth took the drug. Sixty-three percent (63.0%) took it at the correct time, and 54.0% experienced at
least one minor side effect. No serious adverse events reported among enrolled women. Facility-based deliveries
appeared to increase during the program.
Conclusions: The program was moderately effective at achieving high uterotonic coverage of all births. Coverage
of home births was low despite the use of two channels of advance distribution of misoprostol. Although ANC
reached a greater proportion of women in late pregnancy than home visits, 46.3% of expected deliveries did not
receive education or advance distribution of misoprostol. A revised community-based strategy is needed to increase
advance distribution rates and misoprostol coverage rates for home births. Misoprostol for PPH prevention appears
acceptable to women in Liberia. Correct timing of misoprostol self-administration needs improved emphasis during
counseling and education.
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Maternal mortality remains unacceptably high in Liberia,
at 770 maternal deaths per 100,000 live birthsa [1]. Post-
partum hemorrhage (PPH) is the leading cause of mater-
nal mortality, accounting for approximately 42% of
deaths in Liberia and 34% in Africa overall [2]. In Liberia
the health system’s capacity to provide emergency ob-
stetric care is limited by the numbers of surgeons, physi-
cians and midwives, poor geographic access, a weak
referral system and inadequate infrastructure [3]. Most
(95%) of public health facilities were destroyed by the
war [4]. Post-conflict Liberia has made significant strides
in rebuilding its health system. In 2009 a Basic Package
of Health Services was introduced, which includes key
maternal and child health interventions. Despite these
efforts, one-third (34.0%) of pregnant women do not re-
ceive the recommended four or more antenatal care
(ANC) visits [5]. Deliveries in a health facility have in-
creased from 36.9% in 2007 to 55.8% in 2013 [6]. Still,
38.9% of women in Liberia give birth without the assist-
ance of a skilled birth attendant [6].
World Health Organization recommendations for the
prevention of PPH emphasize the provision of a uterotonic
to all women during the third stage of labor [7]. Oxytocin is
the preferred uterotonic for prevention of PPH. Misopros-
tol however is a reasonable alternative, especially in home
birth settings where a qualified provider or injectable oxyto-
cin are unavailable. Misoprostol is a uterotonic used for the
prevention and treatment of PPH [8]. It is manufactured in
tablet form and is taken orally for PPH prevention
(three 200 mcg tablets, total dose 600 mcg) [9]. It is inex-
pensive, easy to store and has an excellent safety profile
[10]. Various studies have demonstrated misoprostol’s ef-
fectiveness in preventing PPH, reducing the need for add-
itional interventions and reducing the need for referrals in
a variety of community-based settings [11]. A number ofTable 1 Population and maternal health parameters for distri
Dis
Total population in each districta 5
Estimated number of pregnant women in a yearb
% ANC coverage – ANC 1
% ANC coverage – ANC 4
% facility based births
Total number of villages in each district
Total # and types of facilities in each district 1 hosp
Number and type of health workers in the districts CM
Trained Traditional Midwives
a2011 population projection (MOHSW).
bbased on the crude birth rate of 45.0 (MOHSW).
cNational level (LDHS 2013).
dNational level (LDHS 2007) 2013 data not yet available.community-based programs for PPH prevention at home
birth using misoprostol have been safely conducted with a
variety of cadres involved in drug distribution [12]. Advo-
cates are calling for a scale up of this approach [13].
It is recognized that the distribution of misoprostol
through community health workers (CHWs) for PPH
prevention could be a significant step in reducing mater-
nal deaths in low-resource settings [14]. This article con-
tributes evidence concerning the safety and effectiveness
of advance distribution for self-administration of miso-
prostol immediately after birth for PPH prevention, in
settings where oxytocin use is not feasible.
Methods
Study setting
To reduce mortality from PPH the Liberia Ministry of
Health and Social Welfare (MOHSW) is implementing two
concurrent strategies to increase uterotonic coverage. The
first aims to increase use of active management of the third
stage of labor (AMTSL) at institutional deliveries, with a
focus on the provision of oxytocin as part of active manage-
ment. The second is to study counseling of pregnant
women either during ANC or home visits by a health
worker and the advance distribution of misoprostol to
those women late in pregnancy for use at home births.
Both interventions were implemented simultaneously
in two districts of Grand Bassa County in 2012 and
2013. District #3 and Campwood districts were selected
for this evaluation based on Ministry of Health and So-
cial Welfare (MOHSW) priorities, compelling public
health need, interest of the district leadership and exist-
ing program funding support from USAID. Because
pregnant women from Campwood district often seek
services in Fenutoli of neighboring Bong County and
vice versa, the Fenutoli population and clinic were in-
cluded in the Campwood parameters in Table 1.ct #3 and Campwood District, Liberia
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This project was approved by the Institutional Review
Board at the Johns Hopkins Bloomberg School of Public
Health, U.S.A (IRB00004451) and the Liberian Insti-
tute for Biomedical Research/National Health Science
Research Ethics Committee (ref EC/LIBR/012/021) in
October 2012.
Study design
The study was implemented as a longitudinal observa-
tional study to assess the ability to achieve high coverage
within the target population of the use of a uterotonic
immediately following birth. The intervention involved
activities at the health facility, community and house-
hold levels by MOHSW staff and unpaid community
volunteers.
Program implementation was preceded by a design
phase wherein the Ministry carefully considered the ben-
efits and limitations of a specific intervention to reduce
postpartum hemorrhage at home birth. The research
questions were: 1) if ANC visits were a feasible and ef-
fective mechanism for providing birth preparedness and
complication readiness (BP/CR) counseling and distrib-
uting misoprostol during pregnancy for PPH prevention
to women who deliver at home; 2) whether trained Dis-
trict Reproductive Health Supervisors (DRHSs) could ef-
fectively provide counseling on BP/CR and distribute
misoprostol to women during home visits; 3) whether
the two strategies together could achieve high coverage
of uterotonic use for PPH prevention either at facility or
home births; 4) whether misoprostol use would be ac-
ceptable to women for PPH prevention; and 5) whether
advance distribution of misoprostol would affect facility
birth rates.
Preparatory activities took place from August to
November 2012, and training was conducted in Decem-
ber 2012. Counseling by health workers and distribution
of misoprostol started in December 2012 and continued
for seven months through June 2013. Approximately
1826 pregnant women age 15–49 were expected to be
enrolled, based on the national crude birth rate of 45.0
births per 1000 population, the total population for the
two districts and the seven-month period of observation.
It was expected that the majority of women would be
reached through ANC, and that the remainder would be
identified through community mapping by trained trad-
itional midwives (TTMs) and targeted for home visits by
the DRHSs. TTMs were trained to identify and educate
pregnant woman about misoprostol, but not to distrib-
ute the drug.
The intervention
The PPH prevention program was designed by the
MOHSW with the technical assistance of Jhpiego throughthe Maternal and Child Health Integrated Program
(MCHIP). It was implemented by the Grand Bassa County
Health Team in Liberia, with technical guidance from Fam-
ily Health Division of the MOHSW and MCHIP staff. As
misoprostol was not available in Liberia, Venture Strategies
Innovations provided the misoprostol and ensured its ap-
propriate importation and entry into the regular national
commodity distribution system of the Liberian National
Drug Service (NDS). Based on evidence from other PPH
prevention studies, a dose of 600 mcg (three tablets, each
200 mcg) misoprostol tablets taken orally was chosen.
Facility-based care at eight of nine health facilities was
strengthened by training the providers who offer ANC, de-
livery services and postnatal care. Health care providers
who attend deliveries were trained on AMTSL, especially
the administration of oxytocin for the prevention of PPH,
and the management of PPH among women who took with
misoprostol at home. Training used competency-based
methods, and all providers were competent at the conclu-
sion of the training, as measured by objective skill assess-
ment tools. For the advance distribution intervention,
health care workers at facilities were trained to provide the
following during ANC: provision of specific messages on
BP/CR and the risks of PPH; identification and consenting
of eligible women; counseling on the use of misoprostol;
and advance distribution of misoprostol to women at or
after 32 weeks of pregnancy for self-administration follow-
ing home birth.
For prevention of PPH at home birth, DRHSs were
trained in counseling and advance distribution of misopros-
tol. DRHSs are certified/registered midwives who work at
hospitals and health clinics and conduct outreach in com-
munities and women’s homes. They supervise other staff,
including TTMs. DRHSs were trained to identify, with the
help of the TTMs, women who had not completed the rec-
ommended ANC visits, to obtain oral consent, and to
counsel them on BP/CR and the importance of facility-
based delivery. If the woman was at eight months of preg-
nancy, the DRHS would provide a dose of misoprostol for
the woman/family to hold until the time of delivery, with
instructions to take the medication immediately following
the birth of the baby (with confirmation of no undiagnosed
second twin) and before the delivery of the placenta. TTMs,
MOHSW-recognized volunteer CHWs, were trained in
community mapping to identify all pregnant women in
their community and to hold community sensitization ac-
tivities. TTMs counseled women late in pregnancy using
pictorial cards on the importance of ANC, birth prepared-
ness, facility-based birth and appropriate preparation for
birth; the danger signs of pregnancy, especially PPH; and
the use of misoprostol for PPH prevention. TTMs did not
distribute the misoprostol, but reinforced the messages
about misoprostol obtained either from the clinics or the
DRHS.
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data recording, using specific data collection tools de-
signed according to their corresponding role.
Counseling by all providers was facilitated by specific-
ally designed, nationally appropriate pictorial message
cards. The educational messages to women regarding
misoprostol were to: store it in a safe place until the
time of delivery; never take the medication prior to the
birth of the baby; ensure that the TTM check for the
presence of a second baby immediately following deliv-
ery at home; and swallow the three tablets with water
immediately after the delivery of the baby and before the
delivery of the placenta. Women were advised about
transient side effects and the possibility of continued
bleeding, even if the medication was taken correctly. In
the face of persistent side effects or continued bleeding,
women were advised to go to a facility. If women chose
delivery in a facility, they were instructed to bring their
misoprostol, which would be returned to the provider
who would destroy it and administer oxytocin. Women
who consumed the medication at home were instructed
to bring the empty blister packets with them to the
health facility during their postpartum visit and new-
born’s first immunization visit.
Misoprostol was obtained from Cipla Pharmaceuticals
(India) in four-tablet strips. Once the medication arrived
in country and was entered into the NDS system, it was
repackaged by the county pharmaceutical system before
distribution to the health facilities and DRHSs. Repack-
aging involved cutting the four-tablet strips into three-
tablet strips and placing them in a small sachet with an
instruction card for use.
Exclusion criteria
Pregnant women who consented and met all of the fol-
lowing eligibility criteria were provided with misoprostol:
aged 15 years or older; had reached 32 weeks gestation
or greater; had no known history of allergy to prosta-
glandins; and had not previously had a cesarean section.
Women who had or developed a chronic disease over
the course of her pregnancy (such as cardiac disease,
diabetes, pregnancy-related hypertension or any other
high-risk condition) were not eligible to receive miso-
prostol. These women were strongly encouraged to de-
liver in a facility and informed about risks involved in
delivery without skilled attendance.
Data collection and analysis
Data on misoprostol distribution were collected at health
facilities using modified ANC registers and at home by
DRHSs using a Community Register for Recording Coun-
seling and a Misoprostol Distribution and Delivery Infor-
mation register. Data were tallied monthly in Monthly
Misoprostol Consumption Log Books. Data on facility-based deliveries and any complications were extracted from
the Labor and Delivery Registers. Data on home births were
reported by TTMs to the health facility and others were
captured during postpartum or first immunization visits. If
women experienced a severe adverse event or were referred
to another facility due to severe complications, providers
recorded data using the Health Facility Admission Form.
Baseline and prospective data on ANC visits and numbers
of deliveries at the facility were collected from routine
reporting into the Health Management Information System
(HMIS).
Among the women who were enrolled and received ad-
vance distribution of misoprostol, 550 were randomly se-
lected from the ANC and DRHS registers for a follow-up
interview postpartum. The sample was arrived by using Epi
Info 7 StatCalc using estimated PPH prevalence at 20% at
95% confidence interval and design effect of 2. Using this
calculation, 500 interviews were required, and 10% add-
itional interviews were added to account for no-responses.
The group that received misoprostol from DRHS was over-
sampled to allow for better understanding of the role that
cadre played in the education of women and provision of
misoprostol and messages. Postpartum interviews were
intended to be conducted by the DRHSs, but it was deter-
mined not to be feasible during implementation due to the
small number of DRHS and their broad array of responsi-
bilities. MCHIP hired dedicated interviewers and trained
them to go to the houses of the selected women to admin-
ister the questionnaire.
All data collection forms were manually reviewed for
completion and accuracy by the MCHIP office in
Liberia. The MCHIP Liberia and Washington teams
assisted with data entry and analysis using Microsoft Ac-
cess. Initial analysis was performed in Washington, DC
using Stata 10.0 (Stata Corp, College Station, TX, USA).
A trend analysis was conducted on AMTSL data to
examine the proportion of women with vaginal births re-
ceiving a uterotonic, as well as the numbers of ANC
visits and births at facilities from baseline to the end of
the program. The misoprostol distribution analysis in-
cluded summary statistics of distribution and cross-
tabulation of key outcome indicators. Results were sum-
marized using frequency distributions and cross
tabulations.
Results and discussion
Misoprostol distribution and coverage
During the seven months of implementation, 1,826 deliver-
ies were expected in the intervention area. Figure 1 presents
data on misoprostol distribution rate by source. A total of
980 (53.7%) of pregnant women were contacted and en-
rolled in the program. Of these, 766 (78.2%) were reached
at the health facilities during ANC visits, and 214 (21.8%)
were reached at home by a DRHS. An estimated 46.3% of
Figure 1 Distribution and uterotonic coverage rates of expected deliveries in intervention qrea (December 2012–June 2013). *Recorded
vaginal deliveries only, excluding the 68 cesarean deliveries (account for 3.7% of expected deliveries) because provision of uterotonic tothose
women is unclear. **Total expected number of home deliveries (calculated as 1758–692 recorded facility deliveries).
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with counseling.
Figure 1 also presents data on uterotonic coverage for
facility-based and home births. A total of 692 vaginal births
at facilities were recorded. The national clinical protocols
do not explicitly state whether a uterotonic should be used
for cesarean section deliveries, and uterotonic use was not
recorded for these deliveries (n = 68). They therefore have
been excluded from coverage calculations.
Among 692 facility-based deliveries, 676 (97.7%) women
received oxytocin, as collected through the project registers
at the health facilities. Before this intervention, policy
allowed only skilled birth attendants to provide a utero-
tonic, which was recorded on the partograph or the
woman’s hospital record. This indicator currently is not
captured in the country’s HMIS.
Among the remainder of estimated deliveries were ex-
pected to have occurred at home (n = 1066), 265 (24.9%)
women took misoprostol for self-administration after home
birth. The overall uterotonic coverage rate for both facility
and home births was 53.5%.ANC Visits and deliveries at health facilities
Data on ANC1 visits, ANC4 visits and deliveries in partici-
pating health facilities were collected from the national
HMIS for the period December 2011–June 2013. (Figure 2)
The monthly average of ANC1 and ANC4 visits during the
intervention period appears to be essentially unchanged
when compared to the same period in the previous year.
The average monthly number of facility deliveries, how-
ever, increased from the 82 during the comparison period
(December 2011–June 2012) to 108 during the interven-
tion period (December 2012–June 2013).
Use of misoprostol for home births
From a sample of 550 women who received advance dis-
tribution of misoprostol and were interviewed postpar-
tum, a large number of women (45.1%) who were
provided misoprostol came to a facility for their delivery
(Table 2). Per protocol, the facility staff destroyed the
tablets and administered oxytocin. Of the 302 women
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Figure 2 Number of deliveries in participating facilities (Dec 2011–June 2013). Blue line represents the number of deliveries. Red line
represents the number of ANC1 visits. Green line represents the number of ANC4 visits.
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about timing of ingestion, and 167 (63.0%) reported they
took the drug at the correct time, and 87 (32.8%) incor-
rectly took the drug after the delivery of the placenta
(Table 3). Three women (1.1%) reported taking the drug
prior to the delivery of the baby. Their reasons are un-
clear, but each woman, when interviewed, reported no
negative effect. Women counseled by ANC providers
were more likely to ingest misoprostol at the correct
time (70.5%) compared to those counseled by a DRHS
(50.5%) (p-value = .002).
Birth planning and knowledge about PPH and
misoprostol
Women interviewed postpartum who were enrolled in
the intervention were asked questions to assess their re-
call of key counseling messages and planning for deliv-
ery. Over 90% of women correctly answered questions
about misoprostol (Table 4). Recall of at least one danger
sign was lower, but greater than 80%. Around half of the
women interviewed had made some arrangements for
transportation for delivery, and slightly higher number
of women had saved money for an emergency. ResultsTable 2 Place of birth and misoprostol use among
enrolled women interviewed postpartum (n = 550)
Indicator Number Percentage
Reported place of delivery for women
(n = 550):
550
Health facility 248 45.1%
Home 302 54.9%
Reported misoprostol use (n = 302): 302
Home births and took misoprostol 265 87.7%
Home births and did NOT take misoprostol 37 12.3%were similar whether women were counseled by a health
care provider or by DRHS.
Women’s satisfaction with misoprostol
Satisfaction was measured by three questions in the post-
partum interview. A very high proportion of women who
reported giving birth at home and taking misoprostol
(n = 265) reported being satisfied with their use of the
medication (Table 5).
Side effects, adverse events, obstetric complications and
referrals
The women who used misoprostol during home births
(n = 265) were asked during the postpartum interview if
they experienced any minor side effects, adverse events
or complications. A total of 143 women (54.0%) indi-
cated that they experienced at least one minor side effect
including dizziness, nausea, shivering, vomiting, fever,
abdominal cramping or watery stools. The majority re-
ported that the side effects subsided after 30–60 mi-
nutes. There were no severe adverse events (defined as
uterine rupture, fever more than 40 degrees, or death of
a woman enrolled in the intervention) reported. Of the
232 misoprostol users who were multigravida, 191
women (82.3%) stated that they bled less than previous
birth experiences. Four women were referred for
retained placenta or bleeding.Health care providers’ and DRHSs’ knowledge of
misoprostol
Health care providers (9) and DRHSs (2) trained in PPH in-
terventions were asked questions to measure their know-
ledge about misoprostol as a follow-up to the training. All
(100%) knew when the woman should self-administer
Table 3 Correct and incorrect use of misoprostol, by source of counseling, among enrolled women interviewed




Health care providers during
ANC (n = 166)
DRHSs during home
visits (n = 99)
Misoprostol taken CORRECTLY (immediately after delivery of baby
AND before delivery of placenta)
167 (63.0%) 117 (70.5%) 50 (50.5%)
Misoprostol taken INCORRECTLY (BEFORE delivery of baby) 3 (1.1%) 2 (1.2%) 1 (1.0%)
Misoprostol taken INCORRECTLY (AFTER delivery of baby and placenta) 87 (32.8%) 45 (27.1%) 42 (42.4%)
No response (data not available) 8 (3.0%) 2 (1.2%) 6 (6.1%)
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prostol works.
Availability of oxytocin and misoprostol at distribution
points
During the intervention one clinic reported stock-out of
misoprostol during one month, due to transportation
problems. There were no recorded stock-outs of oxyto-
cin from any of the facilities.
Discussion
In the low-resource and post-conflict setting of Liberia,
the dual strategies for provision of a PPH prevention
intervention were able to ensure provision of a utero-
tonic for 53.5% of all estimated vaginal deliveries (facility
and home births combined). The intervention found that
it is safe to provide women with a dose of misoprostol in
advance of their delivery for self-administration after the
birth should they deliver at home. There were no adverse
events reported, including among the three women who
took misoprostol prior to the birth of the baby. This is con-
sistent with the review that found self-administration of
misoprostol programs appears to be safe, with an ex-
tremely low rate (.06%) of incorrect antepartum or intra-
partum administration [12]. It however is concerning thatTable 4 Birth planning and knowledge, by source of counseli
postpartum (n = 550)
Indicator Health care pr
(n
Knowledge:
Danger signs during pregnancy (at least one) 339
Signs of excessive bleeding 328
Purpose of misoprostol to reduce bleeding 383
Timing of self-administration 383
Number of pills to take 384
Side effects of misoprostol (at least three side effects) 293
Birth planning:
Arranged for transport during delivery 182
Saved money for delivery 264a substantial proportion (33%) of women incorrectly took
the medication after the delivery of the placenta. While
women’s knowledge on PPH and misoprostol were high,
mistimed self-administration indicates a need for strength-
ened counseling during ANC and home visits.
When women delivered at home and had a dose of
misoprostol, 88% of them reported taking it. This dem-
onstrates that when women have the drug in hand at a
home birth, they are willing to take it. Misoprostol ap-
pears acceptable to pregnant women for PPH preven-
tion. About 98% of the women who took misoprostol
said that if they become pregnant again they will take
the drug and would recommend the drug to a friend or
relative. Only about 50% of these women were willing to
pay for it, due perhaps to expectations that medicines
are provided free of cost per MOHSW policy.
This program used skilled health care providers, both
ANC providers and DRHSs, for distribution. The first
distribution strategy through ANC visits achieved the
higher distribution rate, as was expected. Of the 1826
anticipated births in the catchment area, 41.9% were en-
rolled through ANC, less than the overall national
ANC4 rate of 66%. Of the 1069 women reported in
HMIS who came for ANC visits in late pregnancy, 766
(71.7%) were provided counseling and misoprostol. It isng, among enrolled women interviewed
oviders during ANC
= 401)
DRHSs during home visits
(n = 149)
p-value
(84.5%) 125 (83.9%) 0.799
(81.8%) 136 (91.3%) 0.013
(95.5%) 147 (98.7%) 0.457
(95.5%) 147 (98.7%) 0.003
(95.8%) 147 (98.7%) 0.308
(73.1%) 138 (92.6%) 0.000
(45.4%) 81 (54.4%) 0.106
(65.8%) 103 (69.1%) 0.148
Table 5 Women’s reported satisfaction, by source of counseling, among enrolled women interviewed postpartum who
used misoprostol (n = 265)
Indicator Health care workers during ANC (n = 166) DRHSs during home visits (n = 99*) p-value
Women who were satisfied with use of misoprostol:
Would recommend misoprostol to a friend (n = 259) 165* (100.0%) 93 (98.9%) 0.403
Agreed to pay 5 Liberian Dollars** (n = 260) 92 (55.4%) 50 (53.2%) 0.762
Would take misoprostol for next delivery (n = 259) 162* (98.2%) 92 (97.9%) 0.937
*Note: Some women did not answer all questions, therefore the denominator is not always based on ‘n’.
**Approximately $.06 USD.
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ANC, and this issue needs further exploration during
program expansion.
The household-based advance distribution strategy in-
volving DRHSs to reach pregnant women at home was less
effective. Of the 1826 anticipated births in the catchment
area, 11.7% were enrolled through home visits. Of the total
number of women who delivered at home, only 24.3% were
provided with a uterotonic. By design, the TTMs identified
pregnant women who were not attending ANC and in-
formed the DRHS to visit them at home. The low miso-
prostol distribution rate by DRHS may be due to the small
number of mobilized DRHSs for distribution, logistical con-
straints, hard to reach communities, large catchment area
and other facility-based responsibilities of DRHSs.
These two distribution strategies rely on the health
system (ANC providers and DRHSs) and did not result
in high uterotonic coverage. Global evidence indicates
that greatest distribution and coverage are achieved by
CHWs during home visits [12]. Using TTMs or other
existing CHWs may be considered as an advance distri-
bution strategy to increase the coverage of women who
are unable to attend ANC due to poor geographic access
and likely to deliver at home. In Liberia, TTMs provide
support and are a source of knowledge related to preg-
nancy and maternal health in the community [15]. En-
gaging the TTMs more actively and allowing them to
distribute misoprostol as is done in similar settings in
other countries, may be necessary to achieve the desired
high coverage [16,17]. CHWs may have more contacts,
time and trust to provide counseling, especially concern-
ing the correct timing of self-administration of miso-
prostol. Ultimately, more community engagement and
additional innovative strategies may also be needed to
reach the most remote and vulnerable women.
For facility-based births, the use of oxytocin immediately
following delivery is very high for vaginal births. Records
indicate that almost 98% of women who delivered in the fa-
cility received oxytocin. While it has been suggested that
oxytocin administration in the third stage during labor is
routine in Liberia, it is recommended that provision after a
cesarean section should be detailed in national protocols. It
is promising to note that advance distribution of misopros-
tol for self-administration at home birth does not appear toreduce the numbers of women coming to deliver at facil-
ities. The number of facility births in the two districts
started to increase before the intervention and contin-
ued to increase during the intervention. While the in-
crease and the program may be associated, it is not
possible from this analysis to suggest causality. It is im-
portant, however, to note that facility-based delivery
rates did not decrease during the intervention period as
noted in other programs [12,18].
Anecdotally the County Health Teams reported seeing
fewer cases of PPH during the study, although the study
was not designed to assess the clinical effectiveness of miso-
prostol. The effectiveness of misoprostol in a home birth
setting already has been proven to significantly reduce
acute PPH and mean blood loss [19].
Commodity availability to avoid stock-outs and appropri-
ate packaging of misoprostol (three tablets) must be ad-
dressed during scale-up. As the number of facility-based
births increases, a significant amount of misoprostol will be
returned unused and destroyed. Use and disposition plans
must be developed to prevent wastage, including a consid-
eration of administration of the available misoprostol to
women who present to the facility for delivery. HMIS needs
to incorporate PPH-related monitoring and evaluation, in-
cluding an indicator of uterotonic provision.
Liberia has taken bold steps to transition from an emer-
gency relief model of health service delivery to a function-
ing, decentralized health system. The MOHSW has
focused on interventions to improve the quality of service
provision at health facility level and has institutionalized a
Performance Based Financing (PBF) mechanism. Under
PBF, a mechanism for setting performance targets at the
central, county, and health facility level is established along
with county implementing partners. Counties can either
earn or lose a bonus based on whether they meet the tar-
gets. This accountability framework and quality improve-
ment efforts at health facility level combined with a strong
community focused approach of counseling and misopros-
tol distribution can be very promising in increasing utero-
tonic coverage.
Limitations
This study had numerous limitations. It is not known
who benefited most from this intervention and whether
Smith et al. BMC Pregnancy and Childbirth 2014, 14:189 Page 9 of 10
http://www.biomedcentral.com/1471-2393/14/189those who received the misoprostol were those who
were physically close to health facilities already. Add-
itional data are needed about distance to health facilities
among those women who accept and use the misopros-
tol. As well, the community mapping approach may
yield more exact figures on the actual number of deliver-
ies in the catchment area, and thus more accurate cover-
age figures. The study was not designed or powered to
assess actual impact of the intervention on reducing
PPH incidence or related mortality.
Conclusions
Efforts to increase uterotonic coverage need to reach and
benefit the greatest number of pregnant women, irrespect-
ive of the place of delivery (facility or home). This program
showed that uterotonic coverage in the third stage of labor
was nearly universal (98%) among vaginal births at facilities.
Therefore, focus is needed to increase uterotonic coverage
for home births through the use of CHWs for advance dis-
tribution, given Liberia’s continued high rate of home
births. The combined efforts of DRHSs and health care
providers at ANC yielded a uterotonic rate of 54%.
Endnote
aAt the time the intervention was designed the MMR
was 994 maternal deaths per 100,000 live births. More
recent data from the 2012 WHO, UNICEF, UNFPA and
the World Bank estimates report Trends in Maternal
Mortality 1990–2010 estimate MMR at 770.
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